AsianScientist (Oct. 28, 2016) – TransThera Biosciences Co. Ltd., a startup biotech company specializing in the development of new chemical entity (NCE) drugs, successfully raised Round A Financing of close to US$10 million from a group of investors led by Morningside Ventures.
TransThera’s current portfolio covers disease areas such as oncology, cardiovascular diseases and more. The company is located in the Pharma Valley of Nanjing’s High-Tech Zone.
Morningside Ventures was founded in 1986 in Boston and expanded into China in 1992. Since its establishment, Morningside’s team has been persistent in investing into early-stage life science and healthcare companies in North America, Europe and Asia.
Grand Yangtze Investment, a co-investor of TransThera, is based in Shanghai and has a strong track-record in investing and facilitating the growth of startups.
———
Source: TransThera Biosciences.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
